GRITSTONE BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8134 USD | +6.40% |
|
+10.43% | -60.13% |
| 15/04 | Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform | CI |
| 02/04 | Top Midday Decliners | MT |
| Sales 2024 * | 35.6M 2.97B | Sales 2025 * | 64.31M 5.36B | Capitalization | 86.54M 7.22B |
|---|---|---|---|---|---|
| Net income 2024 * | -134M -11.17B | Net income 2025 * | -132M -11.01B | EV / Sales 2024 * | 3.97 x |
| Net Debt 2024 * | 54.84M 4.57B | Net Debt 2025 * | 63.58M 5.3B | EV / Sales 2025 * | 2.33 x |
| P/E ratio 2024 * |
-0.76
x | P/E ratio 2025 * |
-0.86
x | Employees | 231 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.7% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gritstone bio, Inc.
More recommendations
More press releases
More news
| 1 day | +6.40% | ||
| 1 week | +10.43% | ||
| Current month | -68.35% | ||
| 1 month | -68.59% | ||
| 3 months | -70.42% | ||
| 6 months | -58.29% | ||
| Current year | -60.13% |
1 week
0.69
0.84
1 month
0.672.94
Current year
0.673.17
1 year
0.673.33
3 years
0.6714.42
5 years
0.6735.20
10 years
0.6735.20
| Managers | Title | Age | Since |
|---|---|---|---|
Andrew Allen
FOU | Founder | 57 | 01/15/01 |
| Director of Finance/CFO | 44 | 23/21/23 | |
Karin Jooss
CTO | Chief Tech/Sci/R&D Officer | 59 | 13/16/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrew Allen
FOU | Founder | 57 | 01/15/01 |
Elaine Jones
CHM | Chairman | 69 | 12/19/12 |
Lawrence Corey
BRD | Director/Board Member | 77 | 12/22/12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.8134 | +6.40% | 1,112,845 |
| 25/24/25 | 0.7645 | -5.95% | 1,068,630 |
| 24/24/24 | 0.8129 | +10.06% | 1,886,214 |
| 23/24/23 | 0.7386 | -0.93% | 2,411,711 |
| 22/24/22 | 0.7455 | +1.21% | 3,390,234 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
Sector
Pharmaceuticals
Calendar
30/04/2024
- Neoantigen International Summit
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.8134
USD
Average target price
5.167
USD
Spread / Average Target
+535.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -60.13% | 86.54M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- GRTS Stock
